{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T14:18:15Z","timestamp":1765808295116,"version":"3.37.3"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T00:00:00Z","timestamp":1701302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Italian Ministry of University and Research","award":["PE_00000019"],"award-info":[{"award-number":["PE_00000019"]}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Herein, we present a misleading case of advanced papillary thyroid carcinoma with lung, node, and pleural metastases, initially diagnosed as metastatic lung adenocarcinoma with papillary features, based on the histological and immunohistochemical analysis of a pleural biopsy. Between August 2019 and August 2020, the patient received 2 ineffective lines of systemic therapy, including a first line of chemotherapy with cisplatin and pemetrexed, and a second line of immunotherapy with atezolizumab. Comprehensive genomic profiling by next-generation sequencing on the archival pleural biopsy revealed an NTRK1-TMP3 fusion and comutation of the TERT promoter, commonly found in papillary thyroid carcinoma. After palliative partial thyroidectomy that confirmed the diagnosis of papillary thyroid carcinoma, in February 2021, the patient was enrolled in the STARTRK-2 GO40782 basket trial and received entrectinib, an oral pan-TRK inhibitor specifically targeting NTRK-rearranged tumors. After initially experiencing drug-related grade 2 anorexia, dysgeusia, and neurotoxicity and grade 3 asthenia, the dose was reduced, and an excellent and durable objective response was observed.<\/jats:p>","DOI":"10.1093\/oncolo\/oyad310","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T04:26:56Z","timestamp":1701404816000},"page":"84-88","source":"Crossref","is-referenced-by-count":4,"title":["A Misleading Case of <i>NTRK-<\/i>Rearranged Papillary Thyroid Carcinoma"],"prefix":"10.1093","volume":"29","author":[{"given":"Marco Maria","family":"Germani","sequence":"first","affiliation":[{"name":"Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana , Pisa , Italy"},{"name":"Department of Translational Research and New Technology in Medicine and Surgery, University of Pisa , Pisa , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1019-5983","authenticated-orcid":false,"given":"Chiara","family":"Boccaccio","sequence":"additional","affiliation":[{"name":"Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana , Pisa , Italy"},{"name":"Department of Translational Research and New Technology in Medicine and Surgery, University of Pisa , Pisa , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Matrone","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology, Department of Clinical and Experimental Medicine, Pisa University Hospital , Pisa , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora","family":"Molinaro","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology, Department of Clinical and Experimental Medicine, Pisa University Hospital , Pisa , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greta","family":"Al\u00ec","sequence":"additional","affiliation":[{"name":"Department of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa , Pisa , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirella","family":"Giordano","sequence":"additional","affiliation":[{"name":"Department of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa , Pisa , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5333-9257","authenticated-orcid":false,"given":"Rossella","family":"Elisei","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology, Department of Clinical and Experimental Medicine, Pisa University Hospital , Pisa , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Fontanini","sequence":"additional","affiliation":[{"name":"Department of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa , Pisa , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0520-4841","authenticated-orcid":false,"given":"Chiara","family":"Cremolini","sequence":"additional","affiliation":[{"name":"Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana , Pisa , Italy"},{"name":"Department of Translational Research and New Technology in Medicine and Surgery, University of Pisa , Pisa , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,11,30]]},"reference":[{"key":"2024010523420607700_CIT0001","first-page":"886930","article-title":"Immune related adverse events of the thyroid - a narrative review","volume-title":"Front Endocrinol (Lausanne)","author":"Muir","year":"2022"},{"key":"2024010523420607700_CIT0002","first-page":"593","article-title":"Italian consensus for the classification and reporting of thyroid cytology","volume-title":"J Endocrinol Invest","author":"Nardi","year":"2014"},{"year":"2022","author":"Hoffmann-La","key":"2024010523420607700_CIT0003"},{"author":"FoundationOne CDx | Foundation Medicine","key":"2024010523420607700_CIT0004"},{"key":"2024010523420607700_CIT0005","first-page":"731","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume-title":"Nat Rev Clin Oncol","author":"Cocco","year":"2018"},{"key":"2024010523420607700_CIT0006","first-page":"S600","article-title":"535P Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase (TRK) fusion cancer","volume-title":"Ann Oncol","author":"Brose","year":"2021"},{"key":"2024010523420607700_CIT0007","first-page":"S598","article-title":"533P Efficacy and safety of entrectinib in patients with locally advanced\/metastatic NTRK fusion-positive (NTRK-fp) solid tumours","volume-title":"Ann Oncol","author":"Bazhenova","year":"2021"},{"key":"2024010523420607700_CIT0008","first-page":"R143","article-title":"TERT promoter mutations in thyroid cancer","volume-title":"Endocr Relat Cancer","author":"Liu","year":"2016"},{"key":"2024010523420607700_CIT0009","first-page":"603","article-title":"Highly prevalent TERT promoter mutations in aggressive thyroid cancers","volume-title":"Endocr Relat Cancer","author":"Liu","year":"2013"},{"key":"2024010523420607700_CIT0010","first-page":"e2100442","article-title":"Real-world experience of NTRK fusion\u2013positive thyroid cancer","volume-title":"JCO Precis Oncol","author":"Park","year":"2022"},{"key":"2024010523420607700_CIT0011","first-page":"67","article-title":"Application of immunohistochemistry in thyroid pathology","volume-title":"Arch Pathol Lab Med","author":"Liu","year":"2015"},{"key":"2024010523420607700_CIT0012","first-page":"151793","article-title":"Immunohistochemically detectable thyroglobulin expression in extrathyroidal cancer is 100% specific for thyroidal tumor origin","volume-title":"Ann Diagn Pathol","author":"Steurer","year":"2021"},{"key":"2024010523420607700_CIT0013","first-page":"816","article-title":"A comprehensive analysis of PAX8 expression in human epithelial tumors","volume-title":"Am J Surg Pathol","author":"Laury","year":"2011"},{"key":"2024010523420607700_CIT0014","first-page":"5","article-title":"Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid","volume-title":"Diagn Pathol","author":"El Demellawy","year":"2008"},{"key":"2024010523420607700_CIT0015","first-page":"613099","article-title":"Napsin A expression in human tumors and normal tissues","volume-title":"Pathol Oncol Res","author":"Weidemann","year":"2021"},{"key":"2024010523420607700_CIT0016","first-page":"e220021","article-title":"Poorly differentiated thyroid carcinoma: a clinician\u2019s perspective","volume-title":"Eur Thyroid J","author":"Tong","year":"2022"},{"key":"2024010523420607700_CIT0017","first-page":"621","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume-title":"N Engl J Med","author":"Schlumberger","year":"2015"},{"key":"2024010523420607700_CIT0018","first-page":"69","article-title":"Genomic context of NTRK1\/2\/3 fusion-positive tumours from a large real-world population","volume-title":"NPJ Precis Oncol","author":"Westphalen","year":"2021"},{"key":"2024010523420607700_CIT0019","first-page":"1624","article-title":"TRK fusions are enriched in cancers with uncommon histologies and the absence of canonical driver mutations","volume-title":"Clin Cancer Res","author":"Rosen","year":"2020"},{"key":"2024010523420607700_CIT0020","first-page":"147","article-title":"Molecular characterization of cancers with NTRK gene fusions","volume-title":"Mod Pathol","author":"Gatalica","year":"2019"},{"key":"2024010523420607700_CIT0021","first-page":"1417","article-title":"ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research","volume-title":"Ann Oncol","author":"Marchi\u00f2","year":"2019"},{"key":"2024010523420607700_CIT0022","first-page":"1529","article-title":"Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours","volume-title":"Clin Transl Oncol","author":"Garrido","year":"2021"},{"key":"2024010523420607700_CIT0023","first-page":"1111","article-title":"Pleural effusion in patients with differentiated papillary thyroid cancer","volume-title":"South Med J","author":"Vassilopoulou-Sellin","year":"1994"},{"key":"2024010523420607700_CIT0024","first-page":"1390","article-title":"The molecular signature more than the site of localization defines the origin of the malignancy","volume-title":"Front Oncol","author":"Matrone","year":"2019"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/1\/84\/55119397\/oyad310.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/1\/84\/55119397\/oyad310.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T23:52:33Z","timestamp":1704498753000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/29\/1\/84\/7456504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,30]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,11,30]]},"published-print":{"date-parts":[[2024,1,5]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad310","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2024,1,1]]},"published":{"date-parts":[[2023,11,30]]}}}